Skip to main content
Premium Trial:

Request an Annual Quote

HalioDx Closes €18.5M Series B Round

NEW YORK (GenomeWeb) – French immuno-oncology diagnostics firm HalioDx announced today that it has closed an €18.5 million ($22.7 million) Series B financing round.

Investors in the financing— which follows a €7.5 million Series A round at the time of the company's formation in March 2015 — included Bpifrance, Capricorn Venture Partners, and Amundi Private Equity Funds, as well as existing investors MI Care, Sham Innovation Santé/Turenne, BNP Paribas Development, and Sofipaca.

HalioDx said that the new investment would be used to continue development of its CE-IVD marked Immunoscore colon cancer assay — which measures the density of two T lymphocyte populations to help physicians assess disease prognosis — and to advance Immunoscore assays in additional cancer types. The company also plans to establish commercial operations in the US.

"This Series B financing will enable us to execute our plans faster and enter efficiently the US market," HalioDx CEO Vincent Fert said in a statement. "I am looking forward to see Immunoscore ... in oncologists' routine practice to manage prescriptions across multiple cancer indications."

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.